Relmada Therapeutics Inc (RLMD)

08:57 AM

Why Relmada Therapeutics Inc. stock is a value investor pickJuly 2025 Chart Watch & Free Technical Pattern Based Buy Signals - newser.com

08:57 AM

08:29 AM

Reversal indicators forming on Relmada Therapeutics Inc. stockEarnings Growth Report & High Accuracy Swing Trade Signals - newser.com

08:29 AM

07:56 AM

Will Relmada Therapeutics Inc. stock recover faster than marketPortfolio Risk Report & Free Long-Term Investment Growth Plans - newser.com

07:56 AM

04:06 AM

Combining machine learning predictions for Relmada Therapeutics Inc.Market Performance Recap & Stock Timing and Entry Methods - newser.com

04:06 AM

Oct 11, 2025

Relmada seeking strategic options, stock climbs 5% - MSN

Oct 11, 2025

Oct 11, 2025

Relmada Therapeutics (NASDAQ:RLMD) Upgraded at Wall Street Zen - Defense World

Oct 11, 2025

Oct 10, 2025

D pipelineWeekly Trend Summary & High Return Trade Opportunity Guides - newser.com

Oct 10, 2025

Oct 10, 2025

Weiss Ratings Reiterates Sell (D-) Rating for Relmada Therapeutics (NASDAQ:RLMD) - MarketBeat

Oct 10, 2025

Oct 07, 2025

Relmada appoints Johns Hopkins professor to clinical advisory board - Investing.com

Oct 07, 2025

Oct 07, 2025

Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01 - Investing News Network

Oct 07, 2025

Oct 07, 2025

Relmada Therapeutics, Inc. Appoints Distinguished Urologic Oncologist, Max Kates, Md, to the Clinical Advisory Board - MarketScreener

Oct 07, 2025

Oct 07, 2025

Relmada appoints Johns Hopkins professor to clinical advisory board By Investing.com - Investing.com Australia

Oct 07, 2025

Oct 07, 2025

Relmada Therapeutics appoints Max Kates, MD, to the clinical advisory board to support development of NDV-01 - MarketScreener

Oct 07, 2025

Oct 07, 2025

Relmada Therapeutics Appoints Dr. Max Kates to Clinical Advisory Board to Support NDV-01 Phase 3 Program for Bladder Cancer - Quiver Quantitative

Oct 07, 2025

Oct 07, 2025

Phase 3 H1 2026 — Relmada Taps Max Kates to Guide NDV-01 for NMIBC, Bringing BRIDGE Trial Expertise - Stock Titan

Oct 07, 2025

Oct 06, 2025

Why Relmada Therapeutics Inc. stock is trending among retail tradersMarket Sentiment Summary & Verified Technical Trade Signals - newser.com

Oct 06, 2025

Oct 05, 2025

Using data tools to time your Relmada Therapeutics Inc. exit2025 Trading Recap & Weekly Watchlist for Hot Stocks - newser.com

Oct 05, 2025

Oct 05, 2025

Is Relmada Therapeutics Inc. (4E2) stock undervalued at current pricePortfolio Update Report & Low Drawdown Investment Strategies - newser.com

Oct 05, 2025

Oct 05, 2025

Earnings visualization tools for Relmada Therapeutics Inc.July 2025 Market Mood & Technical Pattern Recognition Alerts - newser.com

Oct 05, 2025

Oct 03, 2025

Relmada Therapeutics Inc. stock retracement – recovery analysis2025 Retail Activity & Precise Swing Trade Entry Alerts - newser.com

Oct 03, 2025

Oct 03, 2025

Using data filters to optimize entry into Relmada Therapeutics Inc.July 2025 Price Swings & Free Expert Approved Momentum Trade Ideas - newser.com

Oct 03, 2025

Oct 02, 2025

What drives Relmada Therapeutics Inc stock priceBlue Chip Stock Analysis & Investment Timing Techniques - earlytimes.in

Oct 02, 2025

Oct 01, 2025

Promising Penny Stocks To Watch In October 2025 - Yahoo Finance

Oct 01, 2025

Oct 01, 2025

Goldman Sachs Group Inc. Invests $33,000 in Relmada Therapeutics, Inc. $RLMD - Defense World

Oct 01, 2025

Sep 26, 2025

Using Python tools to backtest Relmada Therapeutics Inc. strategiesEarnings Beat & High Accuracy Swing Trade Signals - newser.com

Sep 26, 2025